GT
CLDX icon

Glenmede Trust’s Celldex Therapeutics CLDX Stock Holding History

Glenmede Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Buy
+11,267
New +$307K ﹤0.01% 1086
2018
Q2 		– Sell
-195
Closed -$8K – 1978
2018
Q1 		$8K Hold
195
– – ﹤0.01% 2245
2017
Q4 		$8K Buy
+195
New +$8.35K ﹤0.01% 2245
2016
Q3 		– Sell
-47
Closed -$3K – 2588
2016
Q2 		$3K Hold
47
– – ﹤0.01% 2320
2016
Q1 		$2K Hold
47
– – ﹤0.01% 2386
2015
Q4 		$10K Hold
47
– – ﹤0.01% 2064
2015
Q3 		$7K Hold
47
– – ﹤0.01% 2196
2015
Q2 		$17K Buy
+47
New +$18.7K ﹤0.01% 1951
2014
Q2 		– Sell
-120
Closed -$31K – 2331
2014
Q1 		$31K Buy
120
+11
+10% +$4.21K ﹤0.01% 1781
2013
Q4 		$39K Buy
+109
New +$42K ﹤0.01% 1681

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return